Skip header and navigation

Refine By

6 records – page 1 of 1.

The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality.

https://arctichealth.org/en/permalink/ahliterature135938
Source
Prim Care Respir J. 2011 Jun;20(2):178-83
Publication Type
Article
Date
Jun-2011
Author
Vuokko L Kinnula
Tuula Vasankari
Eva Kontula
Anssi Sovijarvi
Olli Saynajakangas
Anne Pietinalho
Author Affiliation
Department of Medicine, Division of Pulmonary Medicine, University of Helsinki, Helsinki, Finland. vuokko.kinnula@helsinki.fi
Source
Prim Care Respir J. 2011 Jun;20(2):178-83
Date
Jun-2011
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Diagnostic Techniques, Respiratory System - standards
Female
Finland - epidemiology
Hospitalization - trends
Humans
Male
Middle Aged
Prevalence
Program Evaluation - methods
Pulmonary Disease, Chronic Obstructive - diagnosis - epidemiology - therapy
Quality Assurance, Health Care
Retrospective Studies
Smoking - adverse effects - epidemiology
Smoking Cessation - statistics & numerical data
Survival Rate - trends
Young Adult
Abstract
The Finnish National Programme for Chronic Bronchitis and Chronic Obstructive Pulmonary Disease (COPD) 1998-2007 was set up to reduce the prevalence of COPD, improve COPD diagnosis and care, reduce the number of moderate to severe cases of the disease, and reduce hospitalisations and treatment costs due to COPD. Over 900 events for 25,000 participating healthcare workers were arranged. The major strengths of this programme included multidisciplinary strategies and web-based guidelines in nearly all primary health care centres around the country.
Data from national registries, epidemiological studies and questionnaires were used to measure whether the goals had been reached.
The prevalence of COPD remained unchanged. Smoking decreased in males from 30% to 26% (p
Notes
Comment In: Prim Care Respir J. 2011 Jun;20(2):109-1021603847
PubMed ID
21431275 View in PubMed
Less detail

HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis.

https://arctichealth.org/en/permalink/ahliterature129744
Source
Hum Immunol. 2012 Jan;73(1):93-100
Publication Type
Article
Date
Jan-2012
Author
Annika Wennerström
Anne Pietinalho
Hanna Vauhkonen
Laura Lahtela
Anil Palikhe
Jouni Hedman
Minna Purokivi
Essi Varkki
Mikko Seppänen
Marja-Liisa Lokki
Olof Selroos
Author Affiliation
Transplantation Laboratory, Haartman Institute, University of Helsinki, 00014 Helsinki, Finland. annika.wennerstrom@helsinki.fi
Source
Hum Immunol. 2012 Jan;73(1):93-100
Date
Jan-2012
Language
English
Publication Type
Article
Keywords
Adult
Alleles
Complement C4a - deficiency - genetics
Complement C4b - deficiency - genetics
DNA Copy Number Variations
Female
Finland
Gene Frequency
Genetic Predisposition to Disease - genetics
Genotype
HLA-DRB1 Chains - genetics
Haplotypes
Humans
Linkage Disequilibrium
Logistic Models
Male
Middle Aged
Prognosis
Sarcoidosis - genetics - metabolism - pathology
Young Adult
Abstract
Sarcoidosis is a multiorgan immune-mediated disease of unknown etiology with varying clinical pictures. We studied 3 genes in the major histocompatibility complex region (HLA-DRB1 and complement C4A and C4B) in patients with resolved disease after a 2-year follow-up (n = 90) and in patients whose disease was still active at that time point (n = 98) and compared them with controls (n = 150). Our primary aim was to detect genetic differences between the patient groups. We observed that the susceptibility allele for sarcoidosis was HLA-DRB1*15:01 (p = 0.011; odds ratio [OR] = 1.67) and the protective allele was HLA-DRB1*01:01 (p = 0.001; OR = 0.43). HLA-DRB1*03:01 was associated with resolving disease when compared with the persistent group (p = 0.011; OR = 2.22). The probability of having resolving disease was even greater if the patient had HLA-DRB1*03:01 and did not have extrapulmonary lesions (p = 0.001; OR = 3.39). By evaluating amino acid variants of the HLA-DRB1 gene, we determined that specific amino acids in pockets 4, 7, and 9 were associated with the prognosis of sarcoidosis. Our results support the importance of HLA-DRB1 as a predisposing gene for sarcoidosis. Particularly, HLA-DRB1*03:01 and polymorphisms of DRB1 pocket residues were associated with a favorable prognosis. Thus, accurate categorization of disease phenotype and HLA-DRB1 sequencing offer a basis for disease course estimation of sarcoidosis.
PubMed ID
22074998 View in PubMed
Less detail

Increase in prevalence of physician-diagnosed asthma in Helsinki during the Finnish Asthma Programme: improved recognition of asthma in primary care? A cross-sectional cohort study.

https://arctichealth.org/en/permalink/ahliterature117417
Source
Prim Care Respir J. 2013 Mar;22(1):64-71
Publication Type
Article
Date
Mar-2013
Author
Annette Kainu
Paula Pallasaho
Päivi Piirilä
Ari Lindqvist
Anssi Sovijärvi
Anne Pietinalho
Author Affiliation
Division of Respiratory Medicine, Department of Medicine, Helsinki University Central Hospital, Peijas Hospital, Vantaa, Finland. annette.kainu@helsinki.fi
Source
Prim Care Respir J. 2013 Mar;22(1):64-71
Date
Mar-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Asthma - diagnosis - epidemiology
Cohort Studies
Cross-Sectional Studies
Female
Finland
Humans
Male
Middle Aged
Prevalence
Primary Health Care
Young Adult
Abstract
The continuing rise in asthma prevalence has been questioned, with recent reports suggesting a plateau.
To assess a 10-year trend in the age-adjusted prevalence of physician-diagnosed asthma, respiratory and allergic symptoms, and use of asthma medication in the adult population of Helsinki during the Finnish Asthma Programme from 1994 to 2004.
Two cross-sectional postal surveys were conducted among random Finnish National Population Registry samples 10 years apart using the same protocol. A total of 6,062 subjects (75.9%) and 2,449 subjects (61.9%) participated in 1996 and 2006, respectively.
The prevalence of physician-diagnosed asthma increased from 6.5% in 1996 to 10.0% in 2006 (p
Notes
Comment In: Prim Care Respir J. 2013 Mar;22(1):13-423426421
PubMed ID
23299455 View in PubMed
Less detail

The quality of spirometric examinations in Finland: results from a national questionnaire survey.

https://arctichealth.org/en/permalink/ahliterature189682
Source
Clin Physiol Funct Imaging. 2002 May;22(3):233-9
Publication Type
Article
Date
May-2002
Author
Päivi Piirilä
Anne Pietinalho
Minna Loponen
Helga Naumanen
Markku Nurminen
Aino Siukola
Olli Korhonen
Kaj Koskela
Anssi Sovijärvi
Author Affiliation
Laboratory of Clinical Physiology, Helsinki University Central Hospital (HUCH), Helsinki, Finland. paivi.piirila@hus.fi
Source
Clin Physiol Funct Imaging. 2002 May;22(3):233-9
Date
May-2002
Language
English
Publication Type
Article
Keywords
Finland
Humans
Pulmonary Disease, Chronic Obstructive - diagnosis
Quality of Health Care
Questionnaires
Reproducibility of Results
Spirometry - standards
Abstract
National treatment programmes for asthma and chronic obstructive pulmonary disease (COPD) have in the past few years increased the need for spirometry in Finland. The purpose of this study was to determine, by means of a national questionnaire survey, the quality and number of spirometric examinations performed in Finland in 1998, the year when the national COPD programme was initiated. We estimated that 395 000-425 000 spirometric examinations were performed in Finland in 1998. The mean quality of spirometry was evaluated as moderate, and the quality index developed for this study indicated an average of scores of 67 (max 100), ranging between 43 and 88 in the whole country. The most common qualitative insufficiencies in spirometric examinations were found in preparation of the subject for the examination, performance of the examination, recognition of a successful spirometric curve and evaluation of reproducibility of the examination. Furthermore, the time reserved in the reports for performing the examination was often very short. However, in comparison with the previous questionnaire survey in Finland (in 1990), the quality of spirometry had markedly improved.
PubMed ID
12076352 View in PubMed
Less detail

Use of spirometry and recording of smoking habits of COPD patients increased in primary health care during national COPD programme.

https://arctichealth.org/en/permalink/ahliterature131107
Source
BMC Fam Pract. 2011;12:97
Publication Type
Article
Date
2011
Author
Tuula Vasankari
Anne Pietinalho
Kalle Lertola
Seppo Yt Junnila
Kari Liippo
Author Affiliation
Finnish Lung Health Association, Sibeliuksenkatu 11 A 1, FI-00250 Helsinki Finland. tuula.vasankari@utu.fi
Source
BMC Fam Pract. 2011;12:97
Date
2011
Language
English
Publication Type
Article
Keywords
Aged
Comorbidity
Early Diagnosis
Electronic Health Records - statistics & numerical data
Female
Finland - epidemiology
Guideline Adherence - statistics & numerical data
Humans
Male
Middle Aged
National Health Programs
Physician's Practice Patterns - trends
Primary Health Care - standards - trends
Program Evaluation
Pulmonary Disease, Chronic Obstructive - diagnosis - prevention & control - therapy
Smoking - adverse effects - prevention & control
Smoking Cessation - statistics & numerical data
Spirometry - utilization
Abstract
In Finland, a national programme for COPD prevention and treatment was developed in 1998. The main goals of the programme were to diagnose COPD as early as possible and to encourage people to quit smoking. The role of primary health care was emphasized in the programme. Our aim was to investigate the use of spirometry and recording of smoking habits of COPD patients in primary health care before and during the COPD programme.
We compared patients with respiratory symptoms or diseases visiting primary health care during 1997 (before programme) and 2002 (during programme). Patients with respiratory symptoms were divided into two groups: COPD patients and "others". Patient records were thoroughly investigated and data retrieved from them.
There was a significant increase in the whole study group from 8.0% to 38.9% in the use of spirometry (p
Notes
Cites: Chest. 2000 Feb;117(2 Suppl):1S-4S10673465
Cites: Eur Respir J. 2010 Oct;36(4):766-7320693258
Cites: Chest. 2000 May;117(5 Suppl 2):372S-5S10843979
Cites: Thorax. 2000 Dec;55(12):987-9911083883
Cites: Chest. 2001 Jun;119(6):1691-511399692
Cites: Eur Respir J. 2001 May;17(5):982-9411488336
Cites: Eur Respir J Suppl. 2003 Jan;39:16s-22s12572697
Cites: Lancet. 2004 Aug 14-20;364(9434):613-2015313363
Cites: J Gen Intern Med. 1990 Jan-Feb;5(1):16-222405112
Cites: JAMA. 1994 Nov 16;272(19):1497-5057966841
Cites: Br J Gen Pract. 1996 May;46(406):277-818762742
Cites: Eur Respir J. 1998 Feb;11(2):284-909551726
Cites: Respir Med. 1999 May;93(5):297-33210464898
Cites: Eur Respir J. 2006 Feb;27(2):397-41216452599
Cites: Prim Care Respir J. 2006 Feb;15(1):48-5716701758
Cites: Eur Respir J. 2008 Jan;31(1):197-20318166597
Cites: Prim Care Respir J. 2008 Mar;17(1):26-3118253681
Cites: Can Fam Physician. 2008 May;54(5):706-1118474704
Cites: BMC Fam Pract. 2008;9:3618564436
Cites: Pharmacoepidemiol Drug Saf. 2009 May;18(5):393-40019288473
Cites: Respir Med. 2010 Mar;104(3):404-1119963361
Cites: Respir Care. 2000 May;45(5):513-3010813228
PubMed ID
21936927 View in PubMed
Less detail

6 records – page 1 of 1.